Modality
Cell Therapy
MOA
IL-23i
Target
Menin
Pathway
Sphingolipid
PVACC
Development Pipeline
Preclinical
~Mar 2020
→ ~Jun 2021
Phase 1
Sep 2021
→ Oct 2030
Phase 1Current
NCT04152304
2,924 pts·ACC
2022-01→2030-10·Not yet recruiting
NCT05899957
1,427 pts·PV
2021-09→2027-12·Terminated
4,351 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-12-051.7y awayPh2 Data· PV
2030-10-064.5y awayPh2 Data· ACC
Trial Timeline
Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P1/2
Termina…
P1/2
Not yet…
Catalysts
Ph2 Data
2027-12-05 · 1.7y away
PV
Ph2 Data
2030-10-06 · 4.5y away
ACC
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04152304 | Phase 1/2 | ACC | Not yet recr... | 2924 | SeizFreq |
| NCT05899957 | Phase 1/2 | PV | Terminated | 1427 | UPCR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-8369 | Eli Lilly | Approved | Menin | |
| NVS-1475 | Novartis | Phase 2 | Menin | |
| GSK-6983 | GSK | Phase 2 | ALK | |
| Motarapivir | GSK | Preclinical | AuroraA | |
| VRT-9481 | Vertex Pharma | Phase 1/2 | Menin | |
| Zenotapinarof | Vertex Pharma | Preclinical | CD38 | |
| Olpainavolisib | Moderna | Phase 1 | Menin | |
| Bemasotorasib | Exelixis | Phase 2 | CD38 | |
| Tirasotorasib | Viking Therapeutics | Phase 1 | CFTR | |
| Cevimavacamten | Denali | NDA/BLA | Menin |